Arvinas Brings Its Parkinson's LRRK2 Degrader ARV-102 to Seoul With Early Biomarker Data
An oral PROTAC that clears LRRK2 reached the brain and improved eye-movement and spinal fluid markers in a small Phase 1 Parkinson's trial.
Summary
Parkinson's disease treatment may be shifting from blocking harmful proteins to removing them. Arvinas presented early Phase 1 data in Seoul on ARV-102, an oral drug that tags the LRRK2 protein for destruction by the cell's own disposal system. LRRK2 overactivity is linked to both inherited and sporadic Parkinson's disease, and to progressive supranuclear palsy. In 24 patients taking 20 to 80 mg or placebo for 28 days, an objective eye-movement measure called saccadic hypometria improved more with higher doses. Spinal fluid markers of lysosomal dysfunction and neuroinflammation fell, while markers of synaptic integrity rose. Greater LRRK2 reduction tracked with both the eye-movement gains and the marker shifts. The study was not designed to show clinical benefit, and the sample is small. Still, it suggests the drug reaches the brain and engages its target in a biologically meaningful way.
Detailed Summary
Parkinson's disease is a major driver of age-related neurological decline, and no approved therapy slows its progression. Arvinas is pursuing a different strategy with ARV-102, an oral PROTAC designed to remove the LRRK2 protein rather than simply block its activity. At the 2026 International Congress of Parkinson's Disease and Movement Disorders in Seoul, the company presented late-breaking Phase 1 biomarker data.
The data came from 24 people with Parkinson's disease who took oral ARV-102 at 20 to 80 mg, or placebo, for 28 days. The drug is built to cross the blood-brain barrier, and earlier Phase 1 results had already shown brain penetration and lower cerebrospinal fluid markers of endolysosomal dysfunction and neuroinflammation. In Seoul, researchers focused on saccadic hypometria, in which rapid eye movements fall short of their targets. After four weeks, the undershoot was less severe than with placebo, and higher doses produced greater improvement.
Cerebrospinal fluid results were consistent. Markers of endolysosomal dysfunction and neuroinflammation fell, while markers of synaptic integrity and axonal guidance rose. Reductions in LRRK2 itself were associated with both the eye-movement improvement and the pathway shifts. This links target removal to downstream biology and a functional readout, which is more persuasive than showing target engagement alone.
For readers, the practical implication is that this is a pipeline development, not a treatment option. ARV-102 is investigational and available only in trials. It does illustrate how targeted protein degradation could be applied to age-related neurodegeneration, including both genetic and idiopathic Parkinson's disease and possibly progressive supranuclear palsy.
The caveats are significant. The sample is small and the treatment period short. The study was not designed to assess clinical efficacy, and biomarker changes do not guarantee that patients will feel or function better. Larger, longer trials must test safety and real-world benefit. Arvinas also cautions that development may not proceed on its timelines, or at all. The results come from company reporting rather than peer-reviewed publication.
Key Findings
- ARV-102 is an oral PROTAC designed to cross the blood-brain barrier and degrade LRRK2 in Parkinson's disease.
- In 24 patients over 28 days, saccadic hypometria improved versus placebo, with greater effects at higher doses.
- Cerebrospinal fluid markers of neuroinflammation and endolysosomal dysfunction fell while synaptic integrity markers rose.
- Greater LRRK2 reduction was associated with both eye-movement improvement and pathway marker shifts.
- The study was not designed to assess clinical efficacy; larger and longer trials are required.
Methodology
This is a news report on a conference presentation of company-sponsored Phase 1 data. It draws on Arvinas statements and earlier AD/PD conference results. The evidence is early biomarker data from 24 patients, not peer-reviewed.
Study Limitations
The sample is small, the treatment lasted only four weeks, and the study did not assess clinical efficacy. Results come from company-reported conference data without peer review, and full dose, safety and statistical details were not given. Verify against the published abstract or paper and later-phase trial results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: